^
Association details:
| Biomarker: | PIK3CA mutation + PTEN mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1933MO - TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
Published date:
09/18/2020
Excerpt:
...PDX446 harbored concomitant PIK3CA and PTEN mutations...PDX446 showed sensitivity to P+F or P+L for >95 days, resembling the patient’s clinical response. Of note, PDX446 was also sensitive to single-agent F or L.
